fbpx

75% of women with unexplained infertility will test positive for BCL6

What is ReceptivaDx™?

The ReceptivaDx test is the first of its kind, developed to test for inflammatory conditions including silent endometriosis, the most common cause of unexplained infertility. Before ReceptivaDx, the only way to test for endometriosis was via surgical aparoscopy. Laparoscopy is an expensive and invasive procedure not usually offered by medical professionals unless major physical symptoms are present.

Endometriosis, or the presence of extra uterine tissue outside of the uterus, is a leading cause of infertility and implantation failure. The ReceptivaDX test is designed to detect inflammation of the uterine lining through the presence of B-cell CLL/lymphoma 6 (BCL6). High levels of BCL6 indicate inflammation of uterine tissue often associated with endometriosis. This can limit the ability of the embryo to stick to the endometrial lining.

If the test results are positive, that means that BCL6 has been detected, confirming the presence of uterine lining inflammation, most often endometriosis. If the test results are negative, it provides high probability that you do not have endometriosis. Either results are useful to you and your physician because they narrow down potential courses of action, increasing your chances of successful conception.

How can the ReceptivaDx™ test help me?

If endometriosis goes untreated, issues with fertility are likely to persist, even throughout IVF treatment. Women who test positive for BCL6 through ReceptivaDx are 5 times less likely to succeed in IVF than women who test negative. 

If you test positive, medical professionals can proceed with two courses of action; hormone treatment or laparoscopic surgery to remove the problematic tissue. Removing uterine inflammation has been proven to naturally increase your chances of fertility. Patients can resume pregnancy attempts with renewed confidence shortly after treatment.

A negative BCL6 test result provides the reassurance that endometriosis is not a current concern and that future attempts at pregnancy are likely to be successful.

While other tests evaluate the quality of embryos or determine optimal embryo transfer windows, only ReceptivaDx™ can accurately detect inflammatory conditions on the uterine lining likely to cause implantation issues. If you have experienced infertility, ReceptivaDX test results can give you peace of mind, a clear plan for treatment, and renewed chances of a successful pregnancy.

Why Is BCL6 testing important for detection of endometriosis?

For many women, the detection of endometriosis comes as a surprise. Although endometriosis has long been associated with pelvic pain, the majority of women who test positive for BCL6 have no symptoms other than their recent fertility issues. Silent endometriosis, or endometriosis with no detectable symptoms, is a common cause of unexplained infertility.

ReceptivaDX can help predict chances for a successful transfer and successful pregnancy. In a study published in the December 2017 issue of Fertility & Sterility—the official journal of the American Society of Reproductive Medicine (ASRM*)—test results for BCL6 enabled physicians to identify women with a poor prognosis for IVF success. If silent endometriosis was left undetected and untreated, chances of a successful pregnancy remained low. If it was detected, medical professionals were then able to assist patients in treatments that increased the chances of pregnancy.

Facts About ReceptivaDX Testing

Research indicates that more than  65% of women with unexplained infertility will test positive for BCL6. Women who test positive have less than an 18% chance of pregnancy in the next transfer attempt and less than an 11% success rate resulting in a live birth. Women who test negative have more than a 70% chance of pregnancy in the next transfer attempt and more than a 59% success rate resulting in a live birth.

ReceptivaDx™ (BCL6 Test) Predicts Chances for a Successful Transfer and Successful Pregnancy

Women testing positive for ReceptivaDx:

• Less than 18% Pregnancy rate in next transfer attempt
• Less than 11% Success rate resulting in live birth

Women testing negative for ReceptivaDx:

• More than 70% Pregnancy rate in next transfer attempt
• More than 59% Success rate resulting in live birth

In a study published in the December 2017 issue of Fertility & Sterility, the official journal of the American Society of Reproductive Medicine (ASRM*), BCL6 was able to identify women with a poor prognosis for IVF success and a successful pregnancy if left undetected and untreated.

 

*Endometrial BCL6 testing for the prediction of in vitro fertilization outcomes: a cohort study. Almquist LD, Likes CE, Stone B, Brown KR, Savaris R, Forstein DA, Miller PB, Lessey BA Fertil Steril. 2017 Dec;108(6):1063-1069

The ReceptivaDxTM Test was developed by Cicero Diagnostics in conjunction with Pathology Consultants, Inc. of Greenville, SC. Pathology Consultants, Inc. is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). As with other laboratory-developed tests, this testing service has not been cleared or approved by the US FDA or any other federal regulatory agencies. Data have not been submitted to or evaluated by Federal regulatory agencies and the test is not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.


Copyright © 2023 ReceptivaDx™ | All Rights Reserved

Privacy Policy | Terms of Service | Disclaimer